Anti-VEGF therapy is effective for neovascular age-related macular degeneration (AMD); however, there are patients who fail to respond to monotherapy alone. Angiogenesis is a complex process that ...
The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of ...
In a 2022 study, Sodhi’s group identified ANGPTL4 as a potential culprit in nonresponse to anti-VEGF drugs, which are ...
Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...
Opens in a new tab or window A novel gene therapy (ABBV-RGX-314) was well tolerated and reduced treatment burden in patients with bilateral neovascular age-related macular degeneration (AMD ...
Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline ...
Reduced well-being and loss of productivity were contributors to the high economic burden in patients with late-stage age-related macular degeneration (AMD) living in the US, Germany, and Bulgaria.
A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...
News Medical on MSN9d
Scientists determine why some patients don't respond well to wet macular degeneration treatment: New drug may bridge gapA study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...
LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024- Appointed Jason Mitchell as chief ...
HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback